gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IOVAHealthcareBiotechnology

Iovance Biotherapeutics, Inc. Common Stock (IOVA)

$8.70−1.47%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$8.53▲ 337.18% in range
Nov 3, 2025Low $1.81 · High $14.86Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Iovance Biotherapeutics closed at $8.70 on Nov 4, down 1.47%, 41.5% below its 52-week closing high. Volume of 18.0M shares was 1.19× its 20-day average (close to normal).

Split-adjusted performance: -32.9% over one month, +112.7% over six months, +346.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $99.31M, up 65.7% from a year earlier, with a net margin of -47.6%.

Short interest was 58.9M shares at the Oct 15 settlement, down 9.1% from the prior report (15.2% of float, 4.4 days to cover).

Market cap$3.94B453.0M shares
Revenue · quarter$99.3M+65.7% YoY
Diluted EPS$-0.11—
P/E · TTM—P/S 12.1×
Net margin-47.6%Gross 56.1%
Dividend yieldNone
52-week range1.81 – 14.86−41.5% from high
Volume18.0M1.19× 20-day avg
Volatility · 60d130.2%Annualised
Short % of float15.2%4.4 days to cover
Net cash$297.7MCash $297.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −41.3%1M −32.9%3M +40.1%6M +112.7%YTD +218.7%1Y +346.2%3Y +135.1%5Y −65.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum96
Revenue growth81
Net margin65
Value (low P/E)—
Size84

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short58.9M−9.1% vs prior
Days to cover4.4Settled Oct 15
% of float15.2%
Short vol. 10d37.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94B
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95BCompare
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26BCompare
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare
TARSTarsus Pharmaceuticals$69.07−4.91%+6.7%+63.9%−343.5%—$3.23BCompare
CRSPCRISPR Therapeutics AG$51.78+3.57%−6.0%+1325.1%−879.6%—$5.01BCompare
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87BCompare
SRRKScholar Rock Holding$46.09+4.80%−2.2%———$5.61BCompare
CGONCG Oncology$67.71+5.70%−0.4%—−6832.8%—$6.00BCompare

News about Iovance Biotherapeutics

All news →
Iovance Gears Up to Report Q3 Earnings: Here's What to ExpectZacks Investment Research · 2d ago▲ PositiveIovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine StrategyGlobeNewswire Inc. · Oct 28, 2026▲ PositiveIovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026GlobeNewswire Inc. · Oct 27, 2026▲ PositiveIovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerGlobeNewswire Inc. · Oct 1, 2026▲ PositiveIOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026Zacks Investment Research · Sep 30, 2026▲ Positive

Quick answers

What does Iovance Biotherapeutics do?
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S.
What is IOVA's market cap?
$3.94B, based on the Nov 4 close of $8.70.
Does Iovance Biotherapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IOVA is sold short?
58.9M shares, 15.2% of float, as of Oct 15, 2026.
What sector is IOVA in?
Healthcare, in the Biotechnology industry.

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

HQ: San Carlos, CA975 employeesListed May 26, 2010iovance.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology